Mike Kagey
Vice President, Translational Medicine Leap Therapeutics
Mike Kagey is a translational biologist with over 15 years of experience in epigenetics and cell signaling. He is the Vice President of Translational Medicine at Leap Therapeutics. There he leads the biomarker and CDx program for DKN-01, a therapeutic antibody targeting the Wnt signaling modulator DKK1, which has undergone multiple phase 2 oncology trials. Previously, Mike led discovery and biomarker efforts at Tensha Therapeutics (acquired by Roche). Mike was a postdoctoral fellow at the Whitehead Institute for Biomedical Research in the laboratory of Richard Young, where he worked on epigenetics and gene regulation in embryonic stem cells and cancer cells.
Seminars
Wednesday 22nd July 2026
Plasma DKK1 Levels are Associated with DKN-01 Clinical Activity in Colorectal Cancer
5:00 pm
- Peripheral DKK1 is elevated in many cancers, often leading to worse clinical outcomes
- DKN-01 in combination with standard of care therapy has demonstrated compelling clinical data in CRC with enhanced activity in patients with elevated plasma DKK1
- CDx development of a plasma DKK1 ELISA assay is undergoing development to support the DKN-01 CRC clinical program
